Norgine wins European Commission marketing authorization for mavorixafor in WHIM syndrome

On 2026-04-29, the European Commission granted marketing authorisation for mavorixafor, sold as XOLREMDI, for patients 12 years and older with WHIM syndrome in the European Union. Norgine said it is the first authorised treatment for this ultra-rare condition in the EU, following a positive CHMP opinion.